Galenica AG (LON:0ROG)
London
· Delayed Price · Currency is GBP · Price in CHF 82.89
-0.26 (-0.31%)
At close: Apr 23, 2025
Galenica AG Revenue
In the year 2024, Galenica AG had annual revenue of 3.93B CHF with 4.65% growth. Galenica AG had revenue of 2.02B in the half year ending December 31, 2024, with 10.41% growth.
Revenue
3.93B CHF
Revenue Growth
+4.65%
P/S Ratio
1.08
Revenue / Employee
493.11K CHF
Employees
7,971
Market Cap
3.75B GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.93B | 174.55M | 4.65% |
| Dec 31, 2023 | 3.76B | 160.81M | 4.47% |
| Dec 31, 2022 | 3.60B | -246.19M | -6.41% |
| Dec 31, 2021 | 3.84B | 356.57M | 10.23% |
| Dec 31, 2020 | 3.48B | 178.60M | 5.40% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Oxford Nanopore Technologies | 183.19M |